Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer

por Aleskandarany, Mohammed A, Green, Andrew R, Benhasouna, Ahmed A, Barros, Fabricio F, Neal, Keith, Reis-Filho, Jorge S, Ellis, Ian O, Rakha, Emad A
Publicado 2012

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer

por Green, Andrew R., Barros, Fabrício F. T., Abdel-Fatah, Tarek M. A., Moseley, Paul, Nolan, Christopher C., Durham, Alice C., Rakha, Emad A., Chan, Stephen, Ellis, Ian O.
Publicado 2014